EGFR and non-small cell lung carcinoma: A retrospective study on EGFRm NSCLC patients with brain metastases revealed a 100% ORR and a 2-year survival rate of 62.5%, suggesting the efficacy of first-generation EGFR-TKI combined with bevacizumab as first-line therapy (23).